Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC).

@article{Dickler2004PhaseIT,
  title={Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC).},
  author={Maura N. Dickler and Hope S Rugo and James F. Caravelli and Edi Brogi and Dana L. Sachs and Katherine S. Panageas and Stephanie Flores and Mark M. Moasser and Larry Norton and Clifford A. Hudis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={2001}
}
2001 Background: Aberrant VEGFR expression in breast tumor cells and EGFR expression in endothelial cells may contribute to tumor growth and progression (Baker, 2002; Kranz, 1999). Preclinical evidence suggests that EGFR blockade may inhibit angiogenesis (Hirata, 2002), and combined blockade of the VEGFR and EGFR pathways may increase anti-tumor activity in xenograft models (Jung, 2002). We performed this two stage phase II study to explore the activity of erlotinib and bevacizumab in MBC, as a… CONTINUE READING

Similar Papers

Loading similar papers…